Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)
Real-world data on gender differences in quality of life among psoriasis patients before and during treatment are scarce. This study analysed data of 748 adults with moderate-to-severe psoriasis enrolled in the Swiss Dermatology Network of Targeted Therapy registry between 2011 and 2023. Quality of life was assessed using the Dermatological Life Quality Index at baseline and at 3, 6, 12, 18, and 24 months. At baseline, women reported significantly lower quality of life than men, with higher Dermatological Life Quality Index scores in the IL-17 inhibitor group (15.0 vs 11.0, p = 0.027), IL-12/23 inhibitor group (7.5 vs 7.0, p = 0.049), and non-biologic therapy group (13.0 vs 9.0, p < 0.001). Although quality of life improved across all subgroups during the follow-up period, women treated with IL-12/23 inhibitors continued to report worse quality of life compared with men after 2 years (p < 0.05), while no significant differences were observed with other therapies. These findings emphasize that women with psoriasis experience lower quality of life at treatment initiation and throughout non-biologic and biologic therapies, underlining the importance of addressing gender-specific differences in the management of psoriasis.
Authors
- Lara Valeska Maul (ORCID: https://orcid.org/0000-0001-9202-0073)
- Simon Francis Thomsen (ORCID: https://orcid.org/0000-0003-1575-9629)
- Thomas M. Kündig (ORCID: https://orcid.org/0000-0003-3863-8766)
- Alexander Egeberg (ORCID: https://orcid.org/0000-0001-8257-1816)
- Kristine Heidemeyer (ORCID: https://orcid.org/0000-0001-9217-6086)
- Jacob Pontoppidan Thyssen (ORCID: https://orcid.org/0000-0003-3770-1743)
- Christoph Schlapbach (ORCID: https://orcid.org/0000-0003-0258-1243)
- Raphael Micheroli (ORCID: https://orcid.org/0000-0002-8918-7304)
- Melike Ak (ORCID: https://orcid.org/0000-0002-5201-9243)
- Christina Sorbe (ORCID: https://orcid.org/0000-0001-5809-3463)
- Ion Birkenmaier (ORCID: https://orcid.org/0000-0003-2782-8580)
- Alexander A. Navarini (ORCID: https://orcid.org/0000-0001-7059-632X)
- Curdin Conrad (ORCID: https://orcid.org/0000-0002-2547-3440)
- Wolf‐Henning Boehncke (ORCID: https://orcid.org/0000-0002-1225-7124)
- Jashin J. Wu (ORCID: https://orcid.org/0000-0002-1722-1892)
- Nikhil Yawalkar (ORCID: https://orcid.org/0000-0003-0024-338X)
- Julia‐Tatjana Maul (ORCID: https://orcid.org/0000-0002-9914-1545)
- Ramtin Lichtenberger (ORCID: https://orcid.org/0000-0002-7682-0238)
- Iker Oyanguren
- Antonio Cozzio (ORCID: https://orcid.org/0000-0002-8299-1746)
- Georgios Kokolakis
Institutions
- University of Bern (CH)
- University of Copenhagen (DK)
- University of Miami (US)
- Universität Hamburg (DE)
- University of Basel (CH)
- University of Zurich (CH)
- Kantonsspital St. Gallen (CH)
- University Hospital of Bern (CH)
- Bispebjerg Hospital (DK)
- University Hospital of Basel (CH)
- Copenhagen University Hospital (DK)
- Humboldt-Universität zu Berlin (DE)
- University Hospital of Zurich (CH)
- University Hospital of Geneva (CH)
- University Medical Center Hamburg-Eppendorf (DE)
- Life Science Zurich (CH)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Acta Dermato Venereologica
- Published
- 2025-02-06
- DOI
- https://doi.org/10.2340/actadv.v105.42296
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Celgene
- Cilag